SAB Biotherapeutics (SABS) Non-Current Debt (2020 - 2022)
SAB Biotherapeutics (SABS) posted Non-Current Debt of $541644.0 for Q4 2022, up 214.84% on a QoQ basis from $172037.0 in Q4 2020.
SAB Biotherapeutics (SABS) Non-Current Debt (2020 - 2022) Analysis & Trends
SAB Biotherapeutics' Non-Current Debt history runs 2 years deep, the most recent figure standing at $541644.0 for Q4 2022.
- Quarterly Non-Current Debt changed N/A year-over-year to $541644.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $541644.0 (changed N/A YoY) and the FY2022 annual result came in at $541644.0, changed N/A from the prior year.
- Non-Current Debt was $541644.0 for Q4 2022 at SAB Biotherapeutics, up from $172037.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $541644.0 in Q4 2022 and bottomed at $172037.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 541,644.00 |
| Dec 31, 2020 | 172,037.00 |